Avatar Precision Therapeutics
Delivering Cellular Precision.
Transforming Medicine.
Our Vision
Avatar Precision Therapeutics is a platform life sciences company advancing proprietary dendrimer constructs that each target specific diseased cells from systemic administration, including neurons, adipocytes, and hepatocytes.
We are working to transform patient outcomes globally through a portfolio of indication specific companies pioneering a new generation of safe, effective, and durable cell-targeted medicines.
Our Companies
Avatar Precision Therapeutics forms and advances focused pharmaceutical companies that apply our novel dendrimer constructs and therapeutic modalities to specific high-value disease areas. Each company is built around a transformative lead asset, accelerated translational development plan, robust IP portfolio, and catalytic financing.
Epilepsy, neuropsychiatric disorders
Cardiometabolic disorders
Acute pain
Intracellular antibodies
Leadership Team
-
Kannan Rangaramanujam, Ph.D.
FOUNDER
Dendrimer platform pioneer with extensive experience translating dendrimer-drug conjugates across inflammatory, neurologic, and systemic disease applications.
-
Sujatha Kannan, M.D.
FOUNDER
Dendrimer pioneer and physician-scientist with clinical and translational expertise in dendrimer-enabled therapeutics and human disease biology.
-
Emmett Cunningham, Jr., M.D., Ph.D.
STRATEGIC ADVISOR
Experienced investor with deep ophthalmology, biotechnology, venture, and therapeutic development experience.
-
Kunal Parikh, Ph.D.
Translational bioengineer and company builder focused on neurotherapeutics, therapeutic devices, and venture development.
Contact Us
We’d love to hear from you.
We are advancing a clinically-validated, targeted drug delivery platform to transform treatment of the world’s most significant health conditions. Whether you're a potential partner, investor, clinician, or researcher, we welcome the opportunity to connect.